Menu

Report Library

All Reports
Hormone Refractory Prostate Cancer Therapies, Phase III

April 17, 2015

A graphical representation of the current and future competitive landscape of all industry-sponsored Phase III (including II/III) and pivotal Phase II ongoing, industry-sponsored HRPC trials, Excludes trials focused on biosimilars, generics, supportive care, metastases (to brain, bone, etc.) and trials started prior to January 1, 2010.

Released Apr-2015, next update Oct-2015.

Trialscape is a powerful visual analysis tool derived from the comprehensive clinical trials intelligence in Citeline’s Trialtrove. Each Trialscape map displays the current and future competitive landscape of pharmaceutical clinical trials in a specific area of research. The Trialscape solution provides graphical representation of pharmaceutical clinical trial timelines in support of strategic decisions in drug development, clinical operations and marketing.

If you would like to learn more about Trialscape before making your purchase, click here for details. In addition to the Trialscape maps available for purchase here, Citeline also offers bundled pricing for all maps in a therapeutic area. If your interest is in areas beyond the current inventory, our analysts will work with you to create a custom deliverable. Please contact analytics@citeline.com for more information.
Disease Group Covered: Oncology
Indications Covered: Castleman's Disease

 Additional Resources: